Last update 05 May 2026

Suzhou Yongxin Biotechnology Co., Ltd.

Private Company|2020

Overview

Tags

Cardiovascular Diseases
Biological products
Antibody
Fusion protein

Disease domain score
A glimpse into the focused therapeutic areas
no Data
No Data
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Top 5 Drug TypeCount
Biological products1
Antibody1
Fusion protein1
Top 5 TargetCount
TRAIL(Tumor necrosis factor ligand superfamily member 10)1
DR5(TNF receptor superfamily member 10b)1

Related

3
Drugs associated with Suzhou Yongxin Biotechnology Co., Ltd.
YF-3
Target-
Mechanism-
Active Org.
Suzhou Yongxin Biotechnology Co., Ltd.
Originator Org.
Suzhou Yongxin Biotechnology Co., Ltd.
Active Indication
ST Elevation Myocardial Infarction [+1]
Inactive Indication-
Drug Highest PhasePhase 1
First Approval Ctry. / Loc.-
First Approval Date-
FICY-101
Target
TRAIL
Mechanism
TRAIL modulators
Active Org.
Suzhou Yongxin Biotechnology Co., Ltd.
Originator Org.
Suzhou Yongxin Biotechnology Co., Ltd.
Active Indication
Myocardial Infarction
Inactive Indication-
Drug Highest PhasePreclinical
First Approval Ctry. / Loc.-
First Approval Date-
WO2024153050
Patent Mining
Target
DR5
Mechanism-
Active Org.
Suzhou Yongxin Biotechnology Co., Ltd.
Originator Org.
Suzhou Yongxin Biotechnology Co., Ltd.
Active Indication
Vascular Diseases
Inactive Indication-
Drug Highest PhaseDiscovery
First Approval Ctry. / Loc.-
First Approval Date-
1
Clinical Trials associated with Suzhou Yongxin Biotechnology Co., Ltd.
CTR20260028
/ Not yet recruitingPhase 1
一项评价YF-3注射液在中国健康成人受试者中安全性、耐受性、药代动力学以及免疫原性特征的单中心、随机、双盲、安慰剂对照、单次给药剂量递增I期临床研究
[Translation] A single-center, randomized, double-blind, placebo-controlled, single-dose escalation phase I clinical study evaluating the safety, tolerability, pharmacokinetics, and immunogenicity of YF-3 injection in healthy adult subjects in China.
100 Clinical Results associated with Suzhou Yongxin Biotechnology Co., Ltd.
Login to view more data
0 Patents (Medical) associated with Suzhou Yongxin Biotechnology Co., Ltd.
Login to view more data
100 Deals associated with Suzhou Yongxin Biotechnology Co., Ltd.
Login to view more data
100 Translational Medicine associated with Suzhou Yongxin Biotechnology Co., Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 08 May 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Discovery
1
1
Preclinical
Phase 1
1
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
YF-3
Myocardial Reperfusion Injury
More
IND Approval
FICY-101
 ( TRAIL )		Myocardial Infarction
More
Preclinical
WO2024153050
 ( DR5 )Patent Mining		Vascular Diseases
More
Discovery
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free